Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy.

摘要: Current strategies for both the primary and secondary prevention of coronary heart disease (CHD) focus on traditional risk factors, such as hypertension, smoking cessation, cholesterol, determinants cardiac profile, with particular emphasis reduction low-density lipoprotein cholesterol (LDL-C) to targeted goal levels endorsed by National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII). Large trials hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have demonstrated varying reductions in cardiovascular events associated similar changes LDL-C levels, suggesting statins may possess additional beneficial effects other factors. Retrospective analyses many statin evaluated association between several polymorphic candidate genes (apolipoprotein E, stromelysin-1, β-fibrinogen, cholesteryl ester transfer protein, lipase, hepatic platelet glycoprotein III) which been identified predictors severity metabolic clinical response therapy. These results suggest that therapy improves plasma lipid profiles all patients, but preferentially benefits individuals who carry a high risk, variant genotype these factors compared wild-type genotype. observations determining individual patient be useful optimizing hypothesis-generating data need prospectively genotyped patients.